Thailandepsins are new small molecule class i HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: A preclinical study of epigenetic ovarian cancer therapy

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Wilson, Andrew J ^a   Cheng, Yi Qiang ^b   Khabele, Dineo ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

HDAC inhibitors; Ovarian cancer; Romidepsin; Thailandepsins

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CASPASE 3; DNA; GLYCOPROTEIN P; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; ROMIDEPSIN; THAILANDEPSIN A; THAILANDEPSIN B; TUBULIN; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84859932807     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-12     Document Type: Article

References (29)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. Integrated genomic analyses of ovarian carcinoma. TCGA, Nature 2011 474 609 615 10.1038/nature10166 21720365
3. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Frew AJ, Johnstone RW, Bolden JE, Cancer Lett 2009 280 125 133 10.1016/j.canlet.2009. 02.042 19359091
4. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Haberland M, Montgomery RL, Olson EN, Nat Rev Genet 2009 10 32 42 10.1038/nrg2485 19065135
5. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW, Mol Cell 2008 30 61 72 10.1016/j.molcel.2008.02. 030 18406327 (Pubitemid 351470157)
6. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, Aladjem MI, Pommier Y, Cancer Res 2010 70 4470 4480 10.1158/0008-5472.CAN-09-3028 20460513
7. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR, et al. Cancer Cell 2010 18 436 447 10.1016/j.ccr.2010.10.022 21075309
8. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, Khabele D, Cancer Biol Ther 2011 12 484 493 10.4161/cbt.12.6.15956 21738006
9. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, et al. J Clin Oncol 2009 27 5410 5417 10.1200/JCO.2008.21.6150 19826128
10. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, et al. Blood 2011 117 5827 5834 10.1182/blood-2010-10- 312603 21355097
11. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S, Cancer Res 2002 62 4916 4921 12208741 (Pubitemid 34984414)
12. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. Wang C, Henkes LM, Doughty LB, He M, Wang D, Meyer-Almes FJ, Cheng YQ, J Nat Prod 2011 74 2031 2038 10.1021/np200324x 21793558
13. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM, Cancer Biol Ther 2007 6 795 801 10.4161/cbt.6.5.4007 17387270 (Pubitemid 47328364)
14. DNA fingerprinting of the NCI-60 cell line panel. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, Weinstein JN, Mol Cancer Ther 2009 8 713 724 10.1158/1535-7163.MCT-08-0921 19372543
15. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. Scudiero DA, Monks A, Sausville EA, J Natl Cancer Inst 1998 90 862 9625177 (Pubitemid 28280554)
16. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, Swisher EM, Mol Cancer Res 2007 5 35 45 10.1158/1541-7786.MCR-06- 0234 17259345
17. TR3/Nur77 in colon cancer cell apoptosis. Wilson AJ, Arango D, Mariadason JM, Heerdt BG, Augenlicht LH, Cancer Res 2003 63 5401 5407 14500374 (Pubitemid 37139857)
18. HDAC4 promotes growth of colon cancer cells via repression of p21. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM, Mol Biol Cell 2008 19 4062 4075 10.1091/mbc.E08-02-0139 18632985
19. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)- ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithi a-5,8,20,23-tetraazabicyclo[8,7, 6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. Xiao JJ, Huang Y, Dai Z, Sadee W, Chen J, Liu S, Marcucci G, Byrd J, Covey JM, Wright J, et al. J Pharmacol Exp Ther 2005 314 467 475 10.1124/jpet.105.083956 15833893 (Pubitemid 41058285)
20. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, Chen J, Sadee W, Byrd J, Marcucci G, Chan KK, J Pharmacol Exp Ther 2005 313 268 276 15634944 (Pubitemid 40411351)
21. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J, Andreeff M, Blood 2006 107 1546 1554 10.1182/blood-2004-10-4126 16223781 (Pubitemid 43242393)
22. Residual gammaH2AX foci as an indication of lethal DNA lesions. Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL, BMC Cancer 2010 10 4 10.1186/1471-2407-10-4 20051134
23. HDAC6 is a microtubule-associated deacetylase. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP, Nature 2002 417 455 458 10.1038/417455a 12024216 (Pubitemid 34563539)
24. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Watson PJ, Fairall L, Santos GM, Schwabe JW, Nature 2012 481 335 340 22230954
25. Total synthesis and stereochemical assignment of burkholdac B, a depsipeptide HDAC inhibitor. Benelkebir H, Donlevy AM, Packham G, Ganesan A, Org Lett 2011 13 6334 6337 10.1021/ol202197q 22091906
26. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, Giaccone G, Pommier Y, Bates SE, Varticovski L, Cell Cycle 2011 10 3119 3128 10.4161/cc.10.18.17190 21900747
27. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Konstantinopoulos PA, Vandoros GP, Papavassiliou AG, Cancer Chemother Pharmacol 2006 58 711 715 10.1007/s00280-005-0182-5 16435156 (Pubitemid 44167398)
28. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? Modesitt SC, Parsons SJ, Gynecol Oncol 2010 119 351 357 10.1016/j.ygyno.2010.06.030 20673975
29. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA, Proc Natl Acad Sci USA 2010 107 14639 14644 10.1073/pnas.1008522107 20679231